NTRA

Key Statistics

Latest News

Signatera Oncology Test Drives Natera’s (NTRA) Growth

Insider Monkey 7 hours ago

Morgan Stanley Cuts Price Target on Natera to $250 From $265, Keeps Overweight Rating

MT Newswires 1 day ago

Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Return Strength

Simply Wall St. 3 days ago

Why Natera (NTRA) Shares Are Falling Today

StockStory 4 days ago

UBS Adjusts Natera Price Target to $290 From $280, Maintains Buy Rating

MT Newswires 5 days ago

Peers in Health Care

Community Sentiment

Sign in to vote

0 votes

Discussion (0)

About Natera, Inc.

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.